PSTVライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:35):

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases...

Stats
本日の出来高	4 498.00
平均出来高	30 041.00
時価総額	7.10M
EPS	$0 ( 2024-04-18 )
次の収益日	( $-0.250 ) 2024-05-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.390
ATR14	$0.0190 (1.14%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-22	Clowes Howard	Buy	2 250	Stock Option (Right to Buy)
2024-02-22	Lafrance Norman D.	Buy	24 073	Stock Option (Right to Buy)
2024-02-22	Hedrick Marc H	Buy	94 012	Stock Option (Right to Buy)
2024-02-22	Sims Andrew John Hugh Macintyre	Buy	18 933	Stock Option (Right to Buy)
2024-02-22	Lenk Robert P	Buy	2 250	Stock Option (Right to Buy)

INSIDER POWER
99.12
Last 94 transactions
Buy: 2 283 640 \| Sell: 1 020 583

Plus Therapeutics Inc 相関

10 最も正の相関
VTSI	0.878
EDIT	0.833
ALVR	0.822
MDVL	0.813
LSBK	0.811
SPRO	0.805

10 最も負の相関
BNIXU	-0.904

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Plus Therapeutics Inc 財務諸表

Annual	2023
収益:	$4.91M
総利益:	$4.17M (84.84 %)
EPS:	$-4.24

FY	2023
収益:	$4.91M
総利益:	$4.17M (84.84 %)
EPS:	$-4.24

FY	2022
収益:	$224 000
総利益:	$-488 000 (-217.86 %)
EPS:	$-11.91

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-1.010

Financial Reports:

No articles found.

Plus Therapeutics Inc

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.

リアルタイムの更新： Plus Therapeutics Inc [PSTV]

Upcoming Earnings Alert